Healthcare Weekly Report: Insilico Medicine Files for HKEX IPO for the Third Time; Shijiazhuang Pharma Group's $1.07B Acquisition of Baik Biologics Terminated

Insilico Medicine Makes Third Attempt at HKEX IPO

On May 8, AI drug discovery company Insilico Medicine submitted an application for listing to the Hong Kong Stock Exchange. Previously, Insilico Medicine had applied for an IPO with the Hong Kong Stock Exchange twice in June 2023 and March 2024, and this is the company's third submission of a listing application. The prospectus shows that Insilico Medicine has generated over 20 assets at clinical or IND stages through its self-developed generative artificial intelligence platform Pharma.AI, three of which have been licensed to international pharmaceutical and healthcare companies, with a total contract value exceeding 2 billion US dollars. (Source: China Securities)

"Shiyao Group's $7.6 Billion Acquisition Plan for Changchun Bcht Biotechnology Co. Terminated"

On May 6, XenoPort announced that Shijiazhuang Pharmaceutical Innovation Co., Ltd. had received the Shenzhen Stock Exchange's "Decision on Terminating the Review of Shijiazhuang Pharmaceutical Innovation Co., Ltd.'s Application for Issuing Shares to Purchase Assets and Raise Supporting Funds." The Shenzhen Stock Exchange agreed to terminate Shijiazhuang Pharmaceutical Innovation’s issuance of shares and payment in cash to purchase assets and raise supporting funds as part of related-party transactions, and to withdraw the application documents. Thus, this “Shijiazhuang Pharmaceutical Group” acquisition, with a total transaction value of up to 7.6 billion yuan, has officially come to an end. (Source: Arterial Network)

Minghui Pharmaceutical Ltd. Announces Exclusive License and Cooperation Agreement with Qilu Pharmaceutical Co., Ltd.

Minghui Pharmaceutical Announces Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical for the Development, Manufacturing, and Commercialization of Its B7-H3 ADC (MHB088C) in Greater China (including mainland China, Hong Kong, Macao, and Taiwan). Under the agreement, Qilu Pharmaceutical will obtain exclusive rights to MHB088C in the aforementioned regions, while Minghui Pharmaceutical is eligible to receive payments totaling up to RMB 1.345 billion, including an upfront payment and near-term milestone payments of RMB 280 million, as well as development, regulatory, and sales milestone payments of RMB 1.065 billion, along with tiered double-digit royalties on net product sales. Minghui Pharmaceutical will retain global rights to MHB088C outside of Greater China and continue to advance its development efforts in those regions. (Source: MedMeridian)

AstraZeneca: Invests $3.4 Billion in Building a New Factory in China

On May 8, 2025, AstraZeneca's new small-molecule drug factory in Wuxi officially broke ground, with a total investment of $4.75 billion (approximately 3.441 billion yuan). The new factory, covering an area of about 30,000 square meters, will be equipped with two sets of advanced continuous tablet manufacturing process equipment and seven sustainable pharmaceutical packaging production lines. It will mainly produce cardiovascular innovative drugs from AstraZeneca's R&D pipeline and is expected to begin operations in the fourth quarter of 2028. Once completed, the factory will further increase the production capacity of the Wuxi production base. Since its operation began in 2001, the Wuxi production base has become one of the key pillars of AstraZeneca’s global supply chain, supplying over 20 products to more than 70 markets worldwide. (Source: Sina Finance)

Beijing Ningmeihao Weisheng Technology Co., Ltd. Secures Tens of Millions in Angel Round Funding

Recently, Beijing Ningmeihao Weisheng Technology Co., Ltd. ("Ningmeihao Weisheng" for short) announced the completion of an angel round of financing worth tens of millions. This round of financing will be used for the research and industrialization process of Ningmeihao Weisheng's gene-editing cell therapy field, supporting its clinical applications in precision anti-aging, diabetes, and other chronic disease treatments, and promoting innovative breakthroughs in the clinical application of "cell + gene" technology. (Source: Arterial Network)

Huan Ying Medical Completes New Round of Financing

Recently, Huan Ying Medical, an ultrasound platform enterprise with independent core component capabilities, announced the completion of a new round of financing. This round was led by Nanshan Venture Capital, with follow-up investments from existing shareholder Shanghai Science Investment Co., Ltd. Hao Yue Capital served as the exclusive financial advisor for this round. Founded in 2020 and based in Shenzhen, Huan Ying Medical is incubated by the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. It holds independent intellectual property rights for ultrasound transducer technology, active interventional catheter technology, and high-frequency ultrasound imaging system technology. With ultrasound as its core platform, the company is expanding into multiple fields such as interventional imaging, high-frequency imaging, ultrasonic pipetting, and ultrasound therapy. It is one of the few companies in the industry capable of mastering the entire chain of core ultrasound technologies. (Source: Arterial Network)

Baiyi Yuan Bio Obtains Tens of Millions of Yuan in New Round of Strategic Financing

Baiyi Edge Bio, a company in the regenerative medicine field, has recently secured financing amounting to tens of millions of RMB. This round of financing was exclusively invested by the listed company Chemshya Pharmaceuticals, and the funds raised will be mainly used for new product development, market expansion, and production line upgrades. M&M Capital served as the long-term strategic chief financial advisor, assisting Baiyi Edge Bio in reaching a comprehensive equity and product strategy cooperation with Chemshya Pharmaceuticals. (Source: Arterial Network)

Aoshark Intelligence Completes Two Rounds of Financing in a Row

Recently, Aosharp Intelligence, a leading exoskeleton robotics technology platform company in China, announced the completion of two consecutive rounds of financing led by Binfu Capital, with continued investment from existing shareholder Guoyi Capital. The funds will primarily be used to expand the consumer-grade exoskeleton robot product line, upgrade core technologies, and promote global industrial implementation, further strengthening its dual-track competitiveness in both industrial and consumer markets. (Source: Arterial Network)